KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Wang, Michael; Muñoz, Javier; Goy, André; L. Locke, Frederick; A. Jacobson, Caron; T. Hill, Brian; M. Timmerman, John; Holmes, Houston; Jaglowski, Samantha; W. Flinn, Ian; A. McSweeney, Peter; B. Miklos, David; M. Pagel, John; José Kersten, Marie; Milpied, Nöel; C. Fung, Henry; S. Topp, Max; Houot, Roch; Beitinjaneh, Amer; Peng, Weimin; Zheng, Lianqing; M. Rossi, John; K. Jain, Rajul; V. Rao, Arati; M. Reagan, Patrick

doi:10.1056/nejmoa1914347

Public

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Published in New England Journal of Medicine • Apr 1, 2020

Authors:

Michael Wang

Javier Muñoz

André Goy

Abstract

BACKGROUND: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients...

Subject

Mantle cell lymphoma

Refractory (planetary science)

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!